R&D teams are starting to advance AI capabilities faster than they can translate them into measurable business value, creating mounting friction between scientific progress and operational reality. In this episode, Aziz Nazha, Global Head of AI Innovations Institute at Incyte Pharmaceuticals, examines how culture, talent, infrastructure, and expectation‑setting determine whether AI meaningfully improves drug discovery and development. He highlights the practical shifts required — from redesigning workflows to disciplined upskilling and targeted validation cycles — to ensure AI adoption accelerates cycle times rather than getting stalled by organizational bottlenecks. This episode is sponsored by Deloitte. Learn how brands like Deloitte work with Emerj and other Emerj Media options at go.emerj.com/partner

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related